If you have been reading about REV-ERB agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-26. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
ISCOM technology was invented in 1982 by Professor Bror Morein at the Swedish University of Agricultural Sciences in Uppsala. The key components of ISCOMs are the Quillaja saponins, which are derived from the bark of the Chilean soap-bark tree Quillaja saponaria Molina. Quillaja saponins are well known for their ability to activate the immune system. It is also known that saponins in general can have toxic side-effects, including the induction of haemolysis. However, when Quillaia saponins, cholesterol and phospholipids are mixed under the specific stoichiometry that forms ISCOMs, this haemolytic activity is practically eliminated, while the adjuvant activity is retained.
Between 2005 and 2007, a Half-Life prequel was in development by Junction Point Studios, with a team led by Warren Spector. The game's plot was intended to explain the backstory behind both Ravenholm and Grigori, showing how it was attacked by the Combine and Grigori's actions prior to the player meeting him in Half-Life 2. It would have included a "magnet gun" which could attract metal objects from remote locations using metallic ball-shaped projectiles. In mid-2007, the project was cancelled and the studio went on to develop the platformer video game Epic Mickey instead, releasing it in 2010. The concept was later given to Arkane Studios, who changed it into a spinoff Half-Life game titled Ravenholm set entirely in the town, but was cancelled by Valve after "9 or 10" levels had already been completed. It was intended to feature Adrian Shephard, the protagonist of Half-Life: Opposing Force, as he made his way through the town with the help of Grigori. Grigori, revealed to have survived his last stand in Half-Life 2, would have gradually mutated into an inhuman being as the result of a serum created from headcrab blood that he believed would protect him from harm. The game would also have introduced several new weapons, such as a nail gun, which could power up doors by acting as an electrical conductor, a plasma weapon and a weaponized leaf blower that could be used to double jump.
A Loner addresses the themes of depression and the need for isolation, as Chanut was affected by these issues during the lockdown period, which coincided with the writing of the album. "A Thousand Miles Away", the last song on the album, marked the onset of Chanut's depression; the lyrics he wrote were about his father's death. David stated that A Loner's musical approach and themes addressed are "purely personal" and that the lyrics "evoke despair without making it an end in itself." "Dark, brooding and unapologetically downbeat on record", wrote Kerrang!'s Sam Law. In 2025, Toufouti stated that he found it interesting to elaborate on a sad individual or subject, as he felt there was material to develop. Saddiction continued in the vein of A Loner by being "more personal, more introspective", said Chanut. Before entering the studio, Toufouti slightly reworked the lyrics of "Neglect" to evoke his relationship with his father, who had just passed away. Lemaire wrote that the song's title, "Kowloon Lights", as well as the large block of buildings on the front cover of Sadditcion, point to a city theme. Chanut responded by elaborating on the feeling of loneliness in crowds, particularly in large cities like Paris, as well as on the mobile phone culture where everyone is focused on their own things. "Kowloon Lights" refers to the former densely populated enclave within the Hong Kong colony. Chanut commented on the grey buildings that made up the city and its colourful neon lights, often depicted in many Hong Kong films of the 1980s.
The Jewish Federations of North America expressed support for TikTok to be banned, while Israel's critics denounced the "criminalisation of pro-Palestinian voices", including on TikTok, which has been used to condemn "Israel's atrocities", according to The New Arab. TikTok was also accused by Malaysia's minister of communications, Fahmi Fadzil of suppressing pro-Palestinian content. The company stated it banned praising Hamas and removed more than 775,000 videos and 14,000 livestreams. There has also been reporting on the trend of Israeli soldiers using TikTok to mock Palestinians and boast about their actions in the Gaza Strip. According to Huda Abudagga, a legal advisor for the British nonprofit Law for Palestine, many of the videos show soldiers partaking in actions, such as the destruction of Palestinian homes as well as the theft of private and public property, that are considered war crimes under international law. Similarly, four legal experts consulted by the New York Times said that the videos "could be used to show unlawful destruction, a violation of the Geneva Conventions." One such video, which showed Israeli soldiers dancing and singing "There are no uninvolved civilians", was included as evidence of genocidal intent in South Africa's case against Israel before the International Court of Justice. In November 2023, Osama bin Laden's 2002 "Letter to the American people" went viral on TikTok and other social media. In the letter, he denounced the US and its support for Israel, and supported al-Qaeda's war against the US as a defensive struggle.
=== Category:EC 5.2 (cis-trans-isomerases) === Category:EC 5.2 FKBP: FKBP1A FKBP1B FKBP2 FKBP3 FKBP4 FKBP5 FKBP6 FKBP8 FKBP9 FKBP10 FKBPL Cyclophilin Parvulin Prolyl isomerase 2-chloro-4-carboxymethylenebut-2-en-1,4-olide isomerase Beta-carotene isomerase Farnesol 2-isomerase Furylfuramide isomerase Linoleate isomerase Maleate isomerase Maleylacetoacetate isomerase Maleylpyruvate isomerase Parvulin Photoisomerase Prolycopene isomerase Prolyl isomerase Retinal isomerase Retinol isomerase Zeta-carotene isomerase
Sources: en.wikipedia.org
Autotrophs that produced organic compounds from CO2, either photosynthetically or by inorganic chemical reactions; Heterotrophs that obtained organics from leakage of other organisms Saprotrophs that absorbed nutrients from decaying organisms Phagotrophs that were sufficiently complex to envelop and digest particulate nutrients, including other organisms. The eukaryotic cell seems to have evolved from a symbiotic community of prokaryotic cells. DNA-bearing organelles like mitochondria and chloroplasts are remnants of ancient symbiotic oxygen-breathing bacteria and cyanobacteria, respectively, where at least part of the rest of the cell may have been derived from an ancestral archaean prokaryote cell. The archean prokaryote cell concept is often termed as the endosymbiotic theory. There is still debate about whether organelles like the hydrogenosome predated the origin of mitochondria, or vice versa: see the hydrogen hypothesis for the origin of eukaryotic cells. How the current lineages of microbes evolved from this postulated community is currently unsolved, but subject of extensive research by biologists, stimulated by new discoveries in genome science.
=== 1.3 === DisplayPort version 1.3 was approved on 15 September 2014. This standard increases overall transmission bandwidth to 32.4 Gbit/s with the new HBR3 mode featuring 8.1 Gbit/s per lane (up from 5.4 Gbit/s with HBR2 in version 1.2), for a total data throughput of 25.92 Gbit/s after factoring in 8b/10b encoding overhead. This bandwidth is enough for a 4K UHD display (3840 × 2160) at 120 Hz with 24 bit/px RGB color, a 5K display (5120 × 2880) at 60 Hz with 30 bit/px RGB color, or an 8K UHD display (7680 × 4320) at 30 Hz with 24 bit/px RGB color. Using Multi-Stream Transport (MST), a DisplayPort port can drive two 4K UHD (3840 × 2160) displays at 60 Hz, or up to four WQXGA (2560 × 1600) displays at 60 Hz with 24 bit/px RGB color. The new standard includes mandatory Dual-mode for DVI and HDMI adapters, implementing the HDMI 2.0 standard and HDCP 2.2 content protection. The Thunderbolt 3 connection standard was originally to include DisplayPort 1.3 capability, but the final release ended up with only version 1.2 for Intel 6000 Series Thunderbolt 3 Controllers. Later Intel 7000 Series Thunderbolt 3 controllers support DisplayPort 1.4 capability including HDR. The VESA's Adaptive Sync feature in DisplayPort version 1.3 remains an optional part of the specification.
The Australasian Proteomics Society (APS) is a learned society formed in 2004 from the Lorne Proteomics Symposia (LPS) meetings. The APS was expanded to include the Australian Electrophoresis and Proteomics Society (a society formed in 1994 in Sydney, Australia and originally called the Australian Electrophoresis Society, part of the International Council of Electrophoresis Societies). The Lorne Proteomics Symposia meetings can trace their roots to the original Specialist Protein Analysis Workshop (SPAW) founded by Robert L. Moritz and Richard J. Simpson. These meetings began in 1994 as an offshoot of the Lorne Protein Meeting. (established in 1974) to address the needs of protein purification and analysis technologies rapidly under development in the 1980s. The founding president and vice president were Simpson and Moritz. The current president is Stuart Cordwell. In 2004, an Australasia-wide committee was formed to fully disseminate the activities of the APS and provide a regional society to include New Zealand and other interested Asian countries to be a focal hub in the Pacific for the Human Proteome Organization. The aims of the APS are to promote and facilitate proteomics research and related topics. The APS acts a liaison body for communication with state and federal government as well as a central point for the coordination of proteome-related programmes and resources. The APS is a member of the Asia Oceania Human Proteome Organization.
He progressed to the quarterfinals after winning over Jaume Munar of Spain, Tomáš Macháč of Czech Republic, and Alexei Popyrin of Australia, all in straight sets. He was defeated in the quarterfinals by eventual bronze medalist Lorenzo Musetti of Italy in straight sets. In the American hard court swing, Zverev reached the quarterfinals in Montréal, losing to Sebastian Korda in three sets. He went on to defend his semifinal points in Cincinnati, losing to Jannik Sinner in an attritive three-set match. At the US Open, he reached the quarterfinals without facing a seeded opponent, with wins over lucky loser Maximilian Marterer, wildcard Alexandre Müller, Tomás Martín Etcheverry and Brandon Nakashima — his 450th career win. With that milestone, he became the second player born in the 1990s, after Grigor Dimitrov, to reach 450 ATP wins. With the win, he qualified for his seventh appearance at the 2024 ATP Finals. Zverev lost in the quarterfinals to Taylor Fritz. At the Paris Masters, Zverev defeated Tallon Griekspoor, Arthur Fils, and Stefanos Tsitsipas to set up a semifinal clash with former champion Holger Rune. He won the match in straight sets to reach the final for the second time at this event. Zverev defeated home crowd favorite Ugo Humbert in the final to clinch his second Masters title of the season and the world No. 2 ranking. Zverev won all three of his group matches at the ATP Finals to reach the semifinals, where he lost to Taylor Fritz in a deciding set tie-break.
== Education == He studied chemistry at the Eötvös Loránd University (Budapest), where he graduated in 1973 and received a PhD in biochemistry in 1976. He worked as a postdoctoral research fellow at the University of California, San Francisco in 1978-1979.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.